1. Compared to usual care, fewer patients in the tocilizumab group died within 28 days of randomization.
2. Patients allocated tocilizumab were more likely to be discharged from the hospital within 28 days.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Hypoxic respiratory failure in patients with COVID-19 is associated with systemic inflammation, alveolar damage,...